Celularity (NASDAQ:CELU) Releases Earnings Results

Celularity (NASDAQ:CELU) released its earnings results on Friday. The company reported ($0.88) earnings per share for the quarter, Zacks reports. Celularity had a negative net margin of 165.22% and a negative return on equity of 459.57%. The firm had revenue of $5.28 million for the quarter.

Celularity Stock Down 2.5%

Celularity stock traded down $0.04 during midday trading on Friday, reaching $1.55. 137,656 shares of the stock traded hands, compared to its average volume of 65,325. The stock has a market cap of $41.37 million, a P/E ratio of -0.49 and a beta of 0.76. The stock’s fifty day moving average is $2.03 and its 200-day moving average is $2.34. Celularity has a 12 month low of $1.00 and a 12 month high of $4.35.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the company. XTX Topco Ltd increased its position in Celularity by 106.4% in the second quarter. XTX Topco Ltd now owns 21,452 shares of the company’s stock worth $42,000 after purchasing an additional 11,057 shares during the last quarter. Acadian Asset Management LLC purchased a new position in shares of Celularity in the 1st quarter worth $34,000. Bank of America Corp DE increased its holdings in shares of Celularity by 1,538.1% in the 2nd quarter. Bank of America Corp DE now owns 37,300 shares of the company’s stock worth $73,000 after buying an additional 35,023 shares during the last quarter. Finally, Vanguard Group Inc. raised its position in shares of Celularity by 35.3% during the 3rd quarter. Vanguard Group Inc. now owns 676,650 shares of the company’s stock valued at $1,401,000 after buying an additional 176,518 shares in the last quarter. 19.02% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several equities analysts have recently commented on CELU shares. Weiss Ratings restated a “sell (d-)” rating on shares of Celularity in a research report on Wednesday, October 8th. Wall Street Zen downgraded Celularity from a “hold” rating to a “sell” rating in a research note on Friday, September 5th. Finally, WBB Securities raised Celularity from a “hold” rating to a “buy” rating and set a $6.00 price target on the stock in a report on Tuesday, September 9th. One analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $6.00.

About Celularity

Celularity Inc, a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases. It operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. The company's lead therapeutic programs include CYCART-19, an allogeneic CAR-T cell for the treatment of non-Hodkin's lymphoma (NHL) and mantle cell lymphoma (MCL); CYNK-001, an allogeneic unmodified natural killer cell that is in Phase I/II clinical trial for the treatment of acute myeloid leukemia (AML); and APPL-001, a genetically modified placental-derived mesenchymal-like adherent stromal cell for the treatment of Crohn's disease.